```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN
 NEWS 20  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS 21  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS 22  FEB 05   German (DE) application and patent publication number format
                   changes

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
```

```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:35:55 ON 13 FEB 2004

=> file medline, uspatful, dgene, embase, wpids, biosis
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 13:36:29 ON 13 FEB 2004

FILE 'USPATFULL' ENTERED AT 13:36:29 ON 13 FEB 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s alzheimer's disease
MISMATCHED QUOTE 'ALZHEIMER'S'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s alzheimer disease
L1       92358 ALZHEIMER DISEASE

=> s l1 and insulin
L2        1284 L1 AND INSULIN

=> s insulin ailments
L3           0 INSULIN AILMENTS

=> s insulin () disease
L4          18 INSULIN (W) DISEASE

=> s l4 and l1
L5           1 L4 AND L1

=> d l5 ti abs ibib tot

L5   ANSWER 1 OF 1  USPATFULL on STN
TI     207 human secreted proteins
AB     The present invention relates to novel human secreted proteins and
       isolated nucleic acids containing the coding regions of the genes
       encoding such proteins. Also provided are vectors, host cells,
       antibodies, and recombinant methods for producing human secreted
       proteins. The invention further relates to diagnostic and therapeutic
       methods useful for diagnosing and treating diseases, disorders, and/or
       conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2003:258639  USPATFULL
TITLE:                  207 human secreted proteins
INVENTOR(S):            Ni, Jian, Germantown, MD, UNITED STATES
                        Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
```

LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Fan, Ping, Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)
	US 1997-48884P	19970606 (60)
	US 1997-48894P	19970606 (60)
	US 1997-48971P	19970606 (60)
	US 1997-48964P	19970606 (60)
	US 1997-48882P	19970606 (60)
	US 1997-48899P	19970606 (60)
	US 1997-48893P	19970606 (60)
	US 1997-48900P	19970606 (60)
	US 1997-48901P	19970606 (60)
	US 1997-48892P	19970606 (60)
	US 1997-48915P	19970606 (60)
	US 1997-49019P	19970606 (60)
	US 1997-48970P	19970606 (60)
	US 1997-48972P	19970606 (60)
	US 1997-48916P	19970606 (60)
	US 1997-49373P	19970606 (60)
	US 1997-48875P	19970606 (60)
	US 1997-49374P	19970606 (60)

US 1997-48917P	19970606	(60)
US 1997-48949P	19970606	(60)
US 1997-48974P	19970606	(60)
US 1997-48883P	19970606	(60)
US 1997-48897P	19970606	(60)
US 1997-48898P	19970606	(60)
US 1997-48962P	19970606	(60)
US 1997-48963P	19970606	(60)
US 1997-48877P	19970606	(60)
US 1997-48878P	19970606	(60)
US 1997-57645P	19970905	(60)
US 1997-57642P	19970905	(60)
US 1997-57668P	19970905	(60)
US 1997-57635P	19970905	(60)
US 1997-57627P	19970905	(60)
US 1997-57667P	19970905	(60)
US 1997-57666P	19970905	(60)
US 1997-57764P	19970905	(60)
US 1997-57643P	19970905	(60)
US 1997-57769P	19970905	(60)
US 1997-57763P	19970905	(60)
US 1997-57650P	19970905	(60)
US 1997-57584P	19970905	(60)
US 1997-57647P	19970905	(60)
US 1997-57661P	19970905	(60)
US 1997-57662P	19970905	(60)
US 1997-57646P	19970905	(60)
US 1997-57654P	19970905	(60)
US 1997-57651P	19970905	(60)
US 1997-57644P	19970905	(60)
US 1997-57765P	19970905	(60)
US 1997-57762P	19970905	(60)
US 1997-57775P	19970905	(60)
US 1997-57648P	19970905	(60)
US 1997-57774P	19970905	(60)
US 1997-57649P	19970905	(60)
US 1997-57770P	19970905	(60)
US 1997-57771P	19970905	(60)
US 1997-57761P	19970905	(60)
US 1997-57760P	19970905	(60)
US 1997-57776P	19970905	(60)
US 1997-57778P	19970905	(60)
US 1997-57629P	19970905	(60)
US 1997-57628P	19970905	(60)
US 1997-57777P	19970905	(60)
US 1997-57634P	19970905	(60)
US 1997-70923P	19971218	(60)
US 1998-92921P	19980715	(60)
US 1998-94657P	19980730	(60)
US 1997-70923P	19971218	(60)
US 1998-92921P	19980715	(60)
US 1998-94657P	19980730	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 32746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

```
     (FILE 'HOME' ENTERED AT 13:35:55 ON 13 FEB 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS' ENTERED AT
     13:36:29 ON 13 FEB 2004
L1         92358 S ALZHEIMER DISEASE
L2          1284 S L1 AND INSULIN
L3             0 S INSULIN AILMENTS
L4            18 S INSULIN () DISEASE
L5             1 S L4 AND L1

=> s glucose therapy and l1
L6             0 GLUCOSE THERAPY AND L1

=> s glucose therapy
L7           159 GLUCOSE THERAPY

=> s insulin therapy\
L8         11261 INSULIN THERAPY\

=> s l8 and l1
L9            10 L8 AND L1

=> s l7 and l1
L10            0 L7 AND L1

=> d l9 ti abs ibib tot

L9   ANSWER 1 OF 10  USPATFULL on STN
TI     Synthetic immunogenic but non-deposit-forming polypeptides and peptides
       homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or
       polyglutamine repeats for induction of an immune response thereto
AB     The present invention relates to immunogenic but non-depositing-forming
       polypeptides or peptides homologous to amyloid β, prion, amylin or
       α-synuclein which can be used alone or conjugated to an
       immunostimulatory molecule in an immunizing composition for inducing an
       immune response to amyloid β peptides and amyloid deposits, to
       prion protein and prion deposits, to amylin and amylin deposits, to
       α-synuclein and deposits containing α-synuclein, or to
       polyglutamine repeats and deposits of proteins containing polyglutamine
       repeats. Described are also antibodies directed against such peptides,
       their generation, and their use in methods of passive immunization to
       such peptides and deposits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2003:238400  USPATFULL
TITLE:                    Synthetic immunogenic but non-deposit-forming
                          polypeptides and peptides homologous to amyloid beta,
                          prion protein, amylin, alpha-synuclein, or
                          polyglutamine repeats for induction of an immune
                          response thereto
INVENTOR(S):              Frangione, Blas, New York, NY, UNITED STATES
                          Wisniewski, Thomas, Statent Island, NY, UNITED STATES
                          Sigurdsson, Einar M., New York, NY, UNITED STATES
PATENT ASSIGNEE(S):       NEW YORK UNIVERSITY (U.S. corporation)

                               NUMBER         KIND    DATE
                          ---------------- ------ --------
PATENT INFORMATION:       US 2003166558      A1   20030904
APPLICATION INFO.:        US 2002-301488     A1   20021121  (10)

                                 NUMBER         DATE
                          ------------------ --------
PRIORITY INFORMATION:     US 2001-331801P    20011121 (60)
```

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DARBY & DARBY P.C., Post Office Box 5257, New York, NY, 10150-5257
NUMBER OF CLAIMS: 115
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Page(s)
LINE COUNT: 4966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:30987 USPATFULL
TITLE: Therapeutic compositions
INVENTOR(S): Veech, Richard L., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): BTG International Limited (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022937	A1	20030130
APPLICATION INFO.:	US 2002-153873	A1	20020524 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-843694, filed on 30 Apr 2001, ABANDONED Continuation of Ser. No. US 1999-397100, filed on 16 Sep 1999, GRANTED, Pat. No. US 6323237 Continuation of Ser. No. WO 1998-US5072, filed on 17 Mar 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant

states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:215082 USPATFULL		
TITLE:	Therapeutic compositions		
INVENTOR(S):	Veech, Richard L., Rockville, MD, United States		
PATENT ASSIGNEE(S):	BTG International Limited, London, United Kingdom (non-U.S. corporation)		

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6323237	B1	20011127
APPLICATION INFO.:	US 1999-397100		19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US5072, filed on 17 Mar 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Reamer, James H.
LEGAL REPRESENTATIVE:	Nixon & Vanderhye
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	2039

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 10 USPATFULL on STN

TI Therapeutic compositions

AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:205943 USPATFULL		
TITLE:	Therapeutic compositions		
INVENTOR(S):	Veech, Richard L., Rockville, MD, United States		
PATENT ASSIGNEE(S):	BTG International Limited (U.S. corporation)		

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2001041736 A1 20011115
APPLICATION INFO.: US 2001-843694 A1 20010430 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-397100, filed on 16 Sep 1999, PENDING Continuation of Ser. No. WO 1998-US5072, filed on 17 Mar 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Nixon & Vanderhye P.C., 8th Floor, 1100 N. Glebe Rd., Arlington, VA, 22201
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:202234 USPATFULL
TITLE: Therapeutic compositions
INVENTOR(S): Veech, Richard Lewis, Rockville, MD, United States
PATENT ASSIGNEE(S): BTG International Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316038	B1	20011113
APPLICATION INFO.:	US 1999-397109		19990916 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-GB5072, filed on 17 Mar 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1821
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 10 USPATFULL on STN
TI Therapeutic compositions (II)
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:134247 USPATFULL		
TITLE:	Therapeutic compositions (II)		
INVENTOR(S):	Veech, Richard Lewis, Rockville, MD, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014696	A1	20010816
APPLICATION INFO.:	US 2001-799124	A1	20010306 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US21015, filed on 15 Sep 1999, UNKNOWN		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-100371P	19980915 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Nixon & Vanderhye, Eighth Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1376		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:44413 USPATFULL
TITLE:	Therapeutic compositions

INVENTOR(S): Veech, Richard L., Rockville, MD, United States
PATENT ASSIGNEE(S): BTG International Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207856	B1	20010327
APPLICATION INFO.:	US 2000-630007		20000731 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1999-397100, filed on 16 Sep 1999 Continuation of Ser. No. WO 1997-US9805072, filed on 17 Mar 1997

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 10 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.

AB Aims/hypothesis. To determine the association of three genes associated with Alzheimer's disease - butyrylcholinesterase (BcHE) on chromosome 3 q, α2 macroglobulin (α2M) on chromosome 12p and apolipoprotein E (ApoE) on chromosome 19 q -with Type II (non-insulin-dependent) diabetes mellitus. Methods. Frequencies of BcHE K variant, α2M insertion and/or deletion polymorphism, the ApoE common polymorphisms and promoter variants at ApoE-491 and -291, were examined by fluorescent RFLP in DNA from 276 United Kingdom Prospective Diabetes Study Type II diabetic subjects and 351 non-diabetic subjects from the Diabetes In Families study. Genetic data in diabetic subjects was analysed in relation to clinical characteristics and islet function as assessed by the requirement for **insulin therapy** 6 years after randomisation.
Results. The BcHE K variant allele was more common among Type II diabetic subjects (D) than non-diabetic subjects (ND) (22.8% D vs 15.8% ND; p = 0.00017). Subjects homozygous for the variant were more frequent in the diabetic group (5.8% D vs 2.6% ND: p = 0.00056). The K variant allele frequency was not associated with a requirement for **insulin therapy** (29.0% insulin-requiring vs 21.8% non-insulin-requiring; p = 0.121). There were no associations of α2M and ApoE polymorphisms or ApoE promoter variants with clinical characteristics or insulin requirement in diabetic subjects. There were differences in total cholesterol (p = 0.0005) and LDL-cholesterol (p = 0.0009) among non-diabetic subjects in relation to ApoE-491 genotypes.
Conclusion/interpretation. The association of the BcHE gene (3q26) with Type II diabetes could be related to an identified susceptibility locus on chromosome 3q27 but appears to be independent of islet function. The absence of diabetes-specific associations with α2M, ApoE or ApoE promoter variants suggest that these are not important in the onset of hyperglycaemia.

ACCESSION NUMBER: 2002005139 EMBASE
TITLE: Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.
AUTHOR: Hashim Y.; Shepherd D.; Wiltshire S.; Holman R.R.; Levy J.C.; Clark A.; Cull C.A.

```
Connecting via Winsock to STN


Welcome to STN International!  Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2           "Ask CAS" for self-help around the clock
 NEWS  3  SEP 09   CA/CAplus records now contain indexing from 1907 to the
                   present
 NEWS  4  DEC 08   INPADOC: Legal Status data reloaded
 NEWS  5  SEP 29   DISSABS now available on STN
 NEWS  6  OCT 10   PCTFULL: Two new display fields added
 NEWS  7  OCT 21   BIOSIS file reloaded and enhanced
 NEWS  8  OCT 28   BIOSIS file segment of TOXCENTER reloaded and enhanced
 NEWS  9  NOV 24   MSDS-CCOHS file reloaded
 NEWS 10  DEC 08   CABA reloaded with left truncation
 NEWS 11  DEC 08   IMS file names changed
 NEWS 12  DEC 09   Experimental property data collected by CAS now available
                   in REGISTRY
 NEWS 13  DEC 09   STN Entry Date available for display in REGISTRY and CA/CAplus
 NEWS 14  DEC 17   DGENE: Two new display fields added
 NEWS 15  DEC 18   BIOTECHNO no longer updated
 NEWS 16  DEC 19   CROPU no longer updated; subscriber discount no longer
                   available
 NEWS 17  DEC 22   Additional INPI reactions and pre-1907 documents added to CAS
                   databases
 NEWS 18  DEC 22   IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
 NEWS 19  DEC 22   ABI-INFORM now available on STN
 NEWS 20  JAN 27   Source of Registration (SR) information in REGISTRY updated
                   and searchable
 NEWS 21  JAN 27   A new search aid, the Company Name Thesaurus, available in
                   CA/CAplus
 NEWS 22  FEB 05   German (DE) application and patent publication number format
                   changes

 NEWS EXPRESS  DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.
```

```
  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:35:55 ON 13 FEB 2004

=> file medline, uspatful, dgene, embase, wpids, biosis
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'MEDLINE' ENTERED AT 13:36:29 ON 13 FEB 2004

FILE 'USPATFULL' ENTERED AT 13:36:29 ON 13 FEB 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'BIOSIS' ENTERED AT 13:36:29 ON 13 FEB 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

=> s alzheimer's disease
MISMATCHED QUOTE 'ALZHEIMER'S'
Quotation marks (or apostrophes) must be used in pairs,
one before and one after the expression you are setting
off or masking.

=> s alzheimer disease
L1       92358 ALZHEIMER DISEASE

=> s l1 and insulin
L2        1284 L1 AND INSULIN

=> s insulin ailments
L3           0 INSULIN AILMENTS

=> s insulin () disease
L4          18 INSULIN (W) DISEASE

=> s l4 and l1
L5           1 L4 AND L1

=> d l5 ti abs ibib tot

L5   ANSWER 1 OF 1  USPATFULL on STN
TI     207 human secreted proteins
AB     The present invention relates to novel human secreted proteins and
       isolated nucleic acids containing the coding regions of the genes
       encoding such proteins. Also provided are vectors, host cells,
       antibodies, and recombinant methods for producing human secreted
       proteins. The invention further relates to diagnostic and therapeutic
       methods useful for diagnosing and treating diseases, disorders, and/or
       conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:         2003:258639  USPATFULL
TITLE:                    207 human secreted proteins
INVENTOR(S):              Ni, Jian, Germantown, MD, UNITED STATES
                          Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
```

LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Fan, Ping, Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)
	US 1997-48884P	19970606 (60)
	US 1997-48894P	19970606 (60)
	US 1997-48971P	19970606 (60)
	US 1997-48964P	19970606 (60)
	US 1997-48882P	19970606 (60)
	US 1997-48899P	19970606 (60)
	US 1997-48893P	19970606 (60)
	US 1997-48900P	19970606 (60)
	US 1997-48901P	19970606 (60)
	US 1997-48892P	19970606 (60)
	US 1997-48915P	19970606 (60)
	US 1997-49019P	19970606 (60)
	US 1997-48970P	19970606 (60)
	US 1997-48972P	19970606 (60)
	US 1997-48916P	19970606 (60)
	US 1997-49373P	19970606 (60)
	US 1997-48875P	19970606 (60)
	US 1997-49374P	19970606 (60)

US 1997-48917P	19970606	(60)
US 1997-48949P	19970606	(60)
US 1997-48974P	19970606	(60)
US 1997-48883P	19970606	(60)
US 1997-48897P	19970606	(60)
US 1997-48898P	19970606	(60)
US 1997-48962P	19970606	(60)
US 1997-48963P	19970606	(60)
US 1997-48877P	19970606	(60)
US 1997-48878P	19970606	(60)
US 1997-57645P	19970905	(60)
US 1997-57642P	19970905	(60)
US 1997-57668P	19970905	(60)
US 1997-57635P	19970905	(60)
US 1997-57627P	19970905	(60)
US 1997-57667P	19970905	(60)
US 1997-57666P	19970905	(60)
US 1997-57764P	19970905	(60)
US 1997-57643P	19970905	(60)
US 1997-57769P	19970905	(60)
US 1997-57763P	19970905	(60)
US 1997-57650P	19970905	(60)
US 1997-57584P	19970905	(60)
US 1997-57647P	19970905	(60)
US 1997-57661P	19970905	(60)
US 1997-57662P	19970905	(60)
US 1997-57646P	19970905	(60)
US 1997-57654P	19970905	(60)
US 1997-57651P	19970905	(60)
US 1997-57644P	19970905	(60)
US 1997-57765P	19970905	(60)
US 1997-57762P	19970905	(60)
US 1997-57775P	19970905	(60)
US 1997-57648P	19970905	(60)
US 1997-57774P	19970905	(60)
US 1997-57649P	19970905	(60)
US 1997-57770P	19970905	(60)
US 1997-57771P	19970905	(60)
US 1997-57761P	19970905	(60)
US 1997-57760P	19970905	(60)
US 1997-57776P	19970905	(60)
US 1997-57778P	19970905	(60)
US 1997-57629P	19970905	(60)
US 1997-57628P	19970905	(60)
US 1997-57777P	19970905	(60)
US 1997-57634P	19970905	(60)
US 1997-70923P	19971218	(60)
US 1998-92921P	19980715	(60)
US 1998-94657P	19980730	(60)
US 1997-70923P	19971218	(60)
US 1998-92921P	19980715	(60)
US 1998-94657P	19980730	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 32746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

```
      (FILE 'HOME' ENTERED AT 13:35:55 ON 13 FEB 2004)

      FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS' ENTERED AT
      13:36:29 ON 13 FEB 2004
L1         92358 S ALZHEIMER DISEASE
L2          1284 S L1 AND INSULIN
L3             0 S INSULIN AILMENTS
L4            18 S INSULIN () DISEASE
L5             1 S L4 AND L1

=> s glucose therapy and l1
L6             0 GLUCOSE THERAPY AND L1

=> s glucose therapy
L7           159 GLUCOSE THERAPY

=> s insulin therapy\
L8         11261 INSULIN THERAPY\

=> s l8 and l1
L9            10 L8 AND L1

=> s l7 and l1
L10            0 L7 AND L1

=> d l9 ti abs ibib tot

L9   ANSWER 1 OF 10  USPATFULL on STN
TI     Synthetic immunogenic but non-deposit-forming polypeptides and peptides
       homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or
       polyglutamine repeats for induction of an immune response thereto
AB     The present invention relates to immunogenic but non-depositing-forming
       polypeptides or peptides homologous to amyloid β, prion, amylin or
       α-synuclein which can be used alone or conjugated to an
       immunostimulatory molecule in an immunizing composition for inducing an
       immune response to amyloid β peptides and amyloid deposits, to
       prion protein and prion deposits, to amylin and amylin deposits, to
       α-synuclein and deposits containing α-synuclein, or to
       polyglutamine repeats and deposits of proteins containing polyglutamine
       repeats. Described are also antibodies directed against such peptides,
       their generation, and their use in methods of passive immunization to
       such peptides and deposits.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:        2003:238400  USPATFULL
TITLE:                   Synthetic immunogenic but non-deposit-forming
                         polypeptides and peptides homologous to amyloid beta,
                         prion protein, amylin, alpha-synuclein, or
                         polyglutamine repeats for induction of an immune
                         response thereto
INVENTOR(S):             Frangione, Blas, New York, NY, UNITED STATES
                         Wisniewski, Thomas, Statent Island, NY, UNITED STATES
                         Sigurdsson, Einar M., New York, NY, UNITED STATES
PATENT ASSIGNEE(S):      NEW YORK UNIVERSITY (U.S. corporation)

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2003166558      A1   20030904
APPLICATION INFO.:       US 2002-301488     A1   20021121  (10)

                               NUMBER        DATE
                         ------------------ --------
PRIORITY INFORMATION:    US 2001-331801P    20011121 (60)
```

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DARBY & DARBY P.C., Post Office Box 5257, New York, NY, 10150-5257
NUMBER OF CLAIMS: 115
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 33 Drawing Page(s)
LINE COUNT: 4966
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:30987 USPATFULL
TITLE: Therapeutic compositions
INVENTOR(S): Veech, Richard L., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): BTG International Limited (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022937	A1	20030130
APPLICATION INFO.:	US 2002-153873	A1	20020524 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-843694, filed on 30 Apr 2001, ABANDONED Continuation of Ser. No. US 1999-397100, filed on 16 Sep 1999, GRANTED, Pat. No. US 6323237 Continuation of Ser. No. WO 1998-US5072, filed on 17 Mar 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1883
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant

states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:215082 USPATFULL		
TITLE:	Therapeutic compositions		
INVENTOR(S):	Veech, Richard L., Rockville, MD, United States		
PATENT ASSIGNEE(S):	BTG International Limited, London, United Kingdom (non-U.S. corporation)		

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6323237	B1	20011127
APPLICATION INFO.:	US 1999-397100		19990916 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1998-US5072, filed on 17 Mar 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Reamer, James H.
LEGAL REPRESENTATIVE:	Nixon & Vanderhye
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	2039

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 10 USPATFULL on STN

TI Therapeutic compositions

AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:205943 USPATFULL
TITLE:	Therapeutic compositions
INVENTOR(S):	Veech, Richard L., Rockville, MD, United States
PATENT ASSIGNEE(S):	BTG International Limited (U.S. corporation)

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2001041736 A1 20011115
APPLICATION INFO.: US 2001-843694 A1 20010430 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-397100, filed on 16 Sep 1999, PENDING Continuation of Ser. No. WO 1998-US5072, filed on 17 Mar 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Nixon & Vanderhye P.C., 8th Floor, 1100 N. Glebe Rd., Arlington, VA, 22201
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 1889
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2001:202234 USPATFULL
TITLE: Therapeutic compositions
INVENTOR(S): Veech, Richard Lewis, Rockville, MD, United States
PATENT ASSIGNEE(S): BTG International Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6316038	B1	20011113
APPLICATION INFO.:	US 1999-397109		19990916 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1998-GB5072, filed on 17 Mar 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1821
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 10 USPATFULL on STN
TI Therapeutic compositions (II)
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:134247 USPATFULL		
TITLE:	Therapeutic compositions (II)		
INVENTOR(S):	Veech, Richard Lewis, Rockville, MD, United States		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001014696	A1	20010816
APPLICATION INFO.:	US 2001-799124	A1	20010306 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US21015, filed on 15 Sep 1999, UNKNOWN		
	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-100371P	19980915 (60)	
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Nixon & Vanderhye, Eighth Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1376		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 10 USPATFULL on STN
TI Therapeutic compositions
AB Compositions comprising ketone bodies and/or their metabolic precursors are provided that are suitable for administration to humans and animals and which have the properties of, inter alia, (i) increasing cardiac efficiency, particularly efficiency in use of glucose, (ii) for providing energy source, particularly in diabetes and insulin resistant states and (iii) treating disorders caused by damage to brain cells, particularly by retarding or preventing brain damage in memory associated brain areas such as found in Alzheimer's and similar conditions.

These compositions may be taken as nutritional aids, for example for athletes, or for the treatment of medical conditions, particularly those associated with poor cardiac efficiency, insulin resistance and neuronal damage. The invention further provides methods of treatment and novel esters and polymers for inclusion in the compositions of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2001:44413 USPATFULL
TITLE:	Therapeutic compositions

INVENTOR(S):	Veech, Richard L., Rockville, MD, United States
PATENT ASSIGNEE(S):	BTG International Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6207856	B1	20010327
APPLICATION INFO.:	US 2000-630007		20000731 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-397100, filed on 16 Sep 1999 Continuation of Ser. No. WO 1997-US9805072, filed on 17 Mar 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-40858P	19970317 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Reamer, James H.
LEGAL REPRESENTATIVE:	Nixon & Vanderhye
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT:	1949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 10 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

TI Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.

AB Aims/hypothesis. To determine the association of three genes associated with Alzheimer's disease - butyrylcholinesterase (BcHE) on chromosome 3 q, α2 macroglobulin (α2M) on chromosome 12p and apolipoprotein E (ApoE) on chromosome 19 q -with Type II (non-insulin-dependent) diabetes mellitus. Methods. Frequencies of BcHE K variant, α2M insertion and/or deletion polymorphism, the ApoE common polymorphisms and promoter variants at ApoE-491 and -291, were examined by fluorescent RFLP in DNA from 276 United Kingdom Prospective Diabetes Study Type II diabetic subjects and 351 non-diabetic subjects from the Diabetes In Families study. Genetic data in diabetic subjects was analysed in relation to clinical characteristics and islet function as assessed by the requirement for **insulin therapy** 6 years after randomisation.

Results. The BcHE K variant allele was more common among Type II diabetic subjects (D) than non-diabetic subjects (ND) (22.8% D vs 15.8% ND; p = 0.00017). Subjects homozygous for the variant were more frequent in the diabetic group (5.8% D vs 2.6% ND: p = 0.00056). The K variant allele frequency was not associated with a requirement for **insulin therapy** (29.0% insulin-requiring vs 21.8% non-insulin-requiring; p = 0.121). There were no associations of α2M and ApoE polymorphisms or ApoE promoter variants with clinical characteristics or insulin requirement in diabetic subjects. There were differences in total cholesterol (p = 0.0005) and LDL-cholesterol (p = 0.0009) among non-diabetic subjects in relation to ApoE-491 genotypes.

Conclusion/interpretation. The association of the BcHE gene (3q26) with Type II diabetes could be related to an identified susceptibility locus on chromosome 3q27 but appears to be independent of islet function. The absence of diabetes-specific associations with α2M, ApoE or ApoE promoter variants suggest that these are not important in the onset of hyperglycaemia.

ACCESSION NUMBER:	2002005139 EMBASE
TITLE:	Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.
AUTHOR:	Hashim Y.; Shepherd D.; Wiltshire S.; Holman R.R.; Levy J.C.; Clark A.; Cull C.A.

CORPORATE SOURCE: C.A. Cull, Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Woodstock Road, Oxford OX2 6HE, United Kingdom. carole.cull@dtu.ox.ac.uk
SOURCE: Diabetologia, (2001) 44/12 (2227-2230).
Refs: 11
ISSN: 0012-186X CODEN: DBTGAJ
COUNTRY: Germany
DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
017 Public Health, Social Medicine and Epidemiology
022 Human Genetics
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

L9 ANSWER 9 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes.
AB Islet amyloid is found in 90% of patients with Type 2 (non-insulin-dependent) diabetes at post-mortem. More extensive amyloidosis is associated with decreased islet function and requirement for **insulin therapy**. Severity of cerebral amyloidosis in Alzheimer's disease (AD) is increased in subjects with the apolipoprotein E (ApoE) epsilon4 allele. To determine if ApoE genotype was associated with severity of islet amyloidosis and diabetes, samples were genotyped from 32 specimens of post-mortem pancreas and from patients classified by disease progression. DNA was extracted from blood samples from Caucasian patients diagnosed with Type 2 diabetes, at age >40 years, classified according to disease progression: group 1 on oral therapy for at least 10 years from diagnosis, (n=147) and group 2, requiring insulin within 6 years from diagnosis, (n=187). ApoE genotype was determined by restriction-fragment length polymorphism analysis. DNA in pancreatic extracts (23 diabetic; 9 non-diabetic subjects) showed no association of ApoE polymorphisms with either degree of islet amyloidosis or disease severity. The distributions of ApoE epsilon2, epsilon3 and epsilon4 were similar in both clinical patient groups and in the non-diabetic group and unrelated to progression of disease. It is unlikely that the common polymorphisms for the ApoE gene are linked to amyloid formation or progression of islet dysfunction in Type 2 diabetes.
ACCESSION NUMBER: 2003:280234 BIOSIS
DOCUMENT NUMBER: PREV200300280234
TITLE: Apolipoprotein E genotype, islet amyloid deposition and severity of Type 2 diabetes.
AUTHOR(S): Powell, D. S.; Maksoud, H.; Charge, S. B. P.; Moffitt, J. H.; Desai, M.; Da Silva Fihlo, R. L.; Hattersley, A. T.; Stratton, I. M.; Matthews, D. R.; Levy, J. C.; Clark, A. [Reprint Author]
CORPORATE SOURCE: Diabetes Research Laboratories, Oxford Centre for Diabetes Endocrinology and Metabolism, Radcliffe Infirmary, Oxford, OX2 6HE, UK
anne.clark@drl.ox.ac.uk
SOURCE: Diabetes Research and Clinical Practice, (May 2003) Vol. 60, No. 2, pp. 105-110. print.
ISSN: 0168-8227 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 11 Jun 2003
Last Updated on STN: 11 Jun 2003

L9 ANSWER 10 OF 10 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
TI A case of diabetic hyperosmolar nonketotic coma with rhabdomyolysis accompanied by Alzheimer's disease.
AB A-69-year-old demented woman who had appetite loss was referred to this

hospital in June 17, 1997. She was diagnosed as having diabetes mellitus (DM) and Alzheimer's disease. Conventional **insulin therapy** was started. Her basal cortisol level and cortisol circadian rhythm were elevated (29.8 mug/dl at 07 : 00) and the postdexamethasone (1 mg) cortisol level was not completely suppressed (4.7 mug/dl). She was discharged on August 30, 1997. However, she was readmitted because of loss of consciousness on September 6, 1997. Her blood glucose level was 969 mg/dl, serum CK level was 1,137 IU/l, and serum myoglobin level was 1,784 mg/dl. Her CRP was within normal limits and urinary ketone body was negative. She was diagnosed as having hyperosmolar nonketotic coma (HNKC) with rhabdomyolysis. Transfusion of half saline and continuous administration of insulin were started, and on the fifth hospital day, her consciousness and electrolytes substantially returned to normal. CK and myoglobin levels gradually decreased. In this case, the development of HNKC was assumed to be precipitated by an acute viral infection because there were no findings of bacterial infection by diagnostic imaging techniques. The above described clinical data of this patient is suggestive of the close association between the onset of HNKC and the prolonged glucocorticoid hypersecretion under stress conditions that exists in DM when accompanied by Alzheimer's disease.

ACCESSION NUMBER: 2000:5485 BIOSIS
DOCUMENT NUMBER: PREV200000005485
TITLE: A case of diabetic hyperosmolar nonketotic coma with rhabdomyolysis accompanied by Alzheimer's disease.
AUTHOR(S): Azami, Yasushi [Reprint author]
CORPORATE SOURCE: Department of Internal Medicine, Jouhoku Hospital, Kanazawa, Japan
SOURCE: Journal of the Japan Diabetes Society, (1999) Vol. 42, No. 6, pp. 461-465. print.
CODEN: TONYA4. ISSN: 0021-437X.
DOCUMENT TYPE: Article
LANGUAGE: Japanese
ENTRY DATE: Entered STN: 23 Dec 1999
Last Updated on STN: 31 Dec 2001

```
=> d his

     (FILE 'HOME' ENTERED AT 13:35:55 ON 13 FEB 2004)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS' ENTERED AT
     13:36:29 ON 13 FEB 2004
L1         92358 S ALZHEIMER DISEASE
L2          1284 S L1 AND INSULIN
L3             0 S INSULIN AILMENTS
L4            18 S INSULIN () DISEASE
L5             1 S L4 AND L1
L6             0 S GLUCOSE THERAPY AND L1
L7           159 S GLUCOSE THERAPY
L8         11261 S INSULIN THERAPY\
L9            10 S L8 AND L1
L10            0 S L7 AND L1

=> s ionic and hydrophobic compounds
L11          659 IONIC AND HYDROPHOBIC COMPOUNDS

=> s l11 and insulin
L12          191 L11 AND INSULIN

=> s insulin agonist
L13         3106 INSULIN AGONIST

=> s l13 and l12
L14             1 L13 AND L12
```

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 1 USPATFULL on STN
TI 207 human secreted proteins
AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2003:258639 USPATFULL
TITLE: 207 human secreted proteins
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Florence, Charles, Rockville, MD, UNITED STATES
Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Li, Yi, Sunnyvale, CA, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
Fischer, Carrie L., Burke, VA, UNITED STATES
Ferrie, Ann M., Painted Post, NY, UNITED STATES
Fan, Ping, Potomac, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Dillon, Patrick J., Carlsbad, CA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Brewer, Laurie A., St. Paul, MN, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Zeng, Zhizhen, Lansdale, PA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003181692	A1	20030925
APPLICATION INFO.:	US 2001-933767	A1	20010822 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. WO 2001-US5614, filed on 21 Feb 2001, PENDING Continuation-in-part of Ser. No. US 1998-205258, filed on 4 Dec 1998, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184836P	20000224 (60)
	US 2000-193170P	20000329 (60)
	US 1997-48885P	19970606 (60)
	US 1997-49375P	19970606 (60)
	US 1997-48881P	19970606 (60)
	US 1997-48880P	19970606 (60)
	US 1997-48896P	19970606 (60)
	US 1997-49020P	19970606 (60)
	US 1997-48876P	19970606 (60)
	US 1997-48895P	19970606 (60)

US 1997-48884P 19970606 (60)
US 1997-48894P 19970606 (60)
US 1997-48971P 19970606 (60)
US 1997-48964P 19970606 (60)
US 1997-48882P 19970606 (60)
US 1997-48899P 19970606 (60)
US 1997-48893P 19970606 (60)
US 1997-48900P 19970606 (60)
US 1997-48901P 19970606 (60)
US 1997-48892P 19970606 (60)
US 1997-48915P 19970606 (60)
US 1997-49019P 19970606 (60)
US 1997-48970P 19970606 (60)
US 1997-48972P 19970606 (60)
US 1997-48916P 19970606 (60)
US 1997-49373P 19970606 (60)
US 1997-48875P 19970606 (60)
US 1997-49374P 19970606 (60)
US 1997-48917P 19970606 (60)
US 1997-48949P 19970606 (60)
US 1997-48974P 19970606 (60)
US 1997-48883P 19970606 (60)
US 1997-48897P 19970606 (60)
US 1997-48898P 19970606 (60)
US 1997-48962P 19970606 (60)
US 1997-48963P 19970606 (60)
US 1997-48877P 19970606 (60)
US 1997-48878P 19970606 (60)
US 1997-57645P 19970905 (60)
US 1997-57642P 19970905 (60)
US 1997-57668P 19970905 (60)
US 1997-57635P 19970905 (60)
US 1997-57627P 19970905 (60)
US 1997-57667P 19970905 (60)
US 1997-57666P 19970905 (60)
US 1997-57764P 19970905 (60)
US 1997-57643P 19970905 (60)
US 1997-57769P 19970905 (60)
US 1997-57763P 19970905 (60)
US 1997-57650P 19970905 (60)
US 1997-57584P 19970905 (60)
US 1997-57647P 19970905 (60)
US 1997-57661P 19970905 (60)
US 1997-57662P 19970905 (60)
US 1997-57646P 19970905 (60)
US 1997-57654P 19970905 (60)
US 1997-57651P 19970905 (60)
US 1997-57644P 19970905 (60)
US 1997-57765P 19970905 (60)
US 1997-57762P 19970905 (60)
US 1997-57775P 19970905 (60)
US 1997-57648P 19970905 (60)
US 1997-57774P 19970905 (60)
US 1997-57649P 19970905 (60)
US 1997-57770P 19970905 (60)
US 1997-57771P 19970905 (60)
US 1997-57761P 19970905 (60)
US 1997-57760P 19970905 (60)
US 1997-57776P 19970905 (60)
US 1997-57778P 19970905 (60)
US 1997-57629P 19970905 (60)
US 1997-57628P 19970905 (60)
US 1997-57777P 19970905 (60)
US 1997-57634P 19970905 (60)

	US 1997-70923P	19971218 (60)
	US 1998-92921P	19980715 (60)
	US 1998-94657P	19980730 (60)
	US 1997-70923P	19971218 (60)
	US 1998-92921P	19980715 (60)
	US 1998-94657P	19980730 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 32746
CAS INDEXING IS AVAILABLE FOR THIS PATENT.